| Dr Douglas Scott Frenia, MD | |
|
240 Easton Ave, New Brunswick, NJ 08901-1723 | |
| (732) 745-8564 | |
| Not Available |
| Full Name | Dr Douglas Scott Frenia |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 25 Years |
| Location | 240 Easton Ave, New Brunswick, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902969769 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MA72662 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Peter's University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Peter's Healthcare System Physician Associates | 9537337258 | 40 |
| Saint Peters University Hospital | 9931012382 | 110 |
News Archive
By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.
After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.
› Verified 7 days ago
| Entity Name | Saint Peters University Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114924834 PECOS PAC ID: 9931012382 Enrollment ID: O20040112000043 |
News Archive
By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.
After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.
› Verified 7 days ago
| Entity Name | Saint Peter's Healthcare System Physician Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548569361 PECOS PAC ID: 9537337258 Enrollment ID: O20110725000726 |
News Archive
By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.
After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas Scott Frenia, MD 10 N Main St, Cranbury, NJ 08512-3204 Ph: (301) 518-9906 | Dr Douglas Scott Frenia, MD 240 Easton Ave, New Brunswick, NJ 08901-1723 Ph: (732) 745-8564 |
News Archive
By attaching light-emitting genes to infectious bacteria in an experimental system, researchers at University College, Cork, Ireland, have been able to track where in the body the bacteria go - giving an insight into the path of the infection process leading to the development of more targeted treatments.
Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA injection and SYMLIN injection, and its investigational diabetes drug candidates BYDUREON and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
Researchers have identified the primary target of the autoantibodies found in the serum of patients with the blistering skin disorder pemphigus vulgaris.
After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.
› Verified 7 days ago
Jennifer Waldmann, M.D Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 254 Easton Ave, New Brunswick, NJ 08901 Phone: 732-996-6741 | |
Lokesh Lahoti, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-823-3000 | |
Dr. Imran Khan, M.D., PH.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 125 Paterson St, Suite 5200, New Brunswick, NJ 08901 Phone: 732-235-6531 | |
Dr. Robert Louis Wong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 125 Paterson St Ste 5100, New Brunswick, NJ 08901 Phone: 732-235-6583 Fax: 732-235-7238 | |
Eric A Rubin, Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 195 Little Albany St, New Brunswick, NJ 08901 Phone: 732-235-2465 | |
Haris Ishaque Rana, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 240 Easton Ave, New Brunswick, NJ 08901 Phone: 732-745-8564 Fax: 732-745-9156 | |
Amanda Borham, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Robert Wood Johnson Pl, New Brunswick, NJ 08901 Phone: 732-235-7794 Fax: 732-235-7238 |